Adrenocortical carcinoma: Surgical progress or status quo?

Michael L. Kendrick, Ricardo Lloyd, Lori Erickson, David R. Farley, Clive S. Grant, Geoffrey B. Thompson, Charles Rowland, William Francis Young, Jon A. Van Heerden

Research output: Contribution to journalArticle

120 Citations (Scopus)

Abstract

Hypothesis: Outcome of patients with adrenocortical carcinoma (ACC) has improved with the advent of more widely available and higher quality imaging. Operative management strategies and use of adjuvant therapy have not changed. Design: Retrospective review of patient histories, imaging studies, operative data, adjuvant therapy, and outcomes at a single institution. Follow-up was complete for a mean of 53 months. Data was compared with prior institutional experience. Setting: Tertiary care referral center. Patients: All patients undergoing operative management for ACC during the period from 1980 to 1996. Main Outcome Measures: Determinants of recurrence, survival, and the effect of adjuvant therapy on overall outcome. Results: Fifty-eight patients (30 men, 28 women) with a mean age of 53 years underwent primary operative management for ACC. Functional tumors were identified in 27 patients (47%). Mean tumor size was 12.5 cm. Stage according to the TNM staging system (AJCC Cancer Staging Manual) at presentation was I (n=0), II (n=30), III (n=7), and IV (n=21). Surgical management included curative resection in 41 (71%), noncurative resection in 14 (24%), and open biopsy in 3 (5%). Perioperative mortality was 5%. Recurrence occurred in 30 patients (73%) with a median time to recurrence of 17 months. Five-year survival by the Kaplan-Meier method was 37%. Prognostic factors (P<.05) included functional status, stage, and chemotherapy in stage III/IV patients. When compared with our prior institutional experience (1960-1980), current patients were more likely to present with stages I to II (52% vs 34%), have curative resections (71% vs 50%), and have improved 5-year survival (37% vs 16%). Conclusions: (1) Surgical resection remains the principal treatment for stage I to III disease. (2) Adjuvant therapy may improve survival in patients with stage III or IV disease. (3) Current patients were more likely to present at an earlier stage, undergo curative resections, and have improved 5-year survival than institutional historical comparisons.

Original languageEnglish (US)
Pages (from-to)543-549
Number of pages7
JournalArchives of Surgery
Volume136
Issue number5
StatePublished - 2001

Fingerprint

Adrenocortical Carcinoma
Survival
Neoplasm Staging
Tertiary Care Centers
Recurrence
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Surgery

Cite this

Kendrick, M. L., Lloyd, R., Erickson, L., Farley, D. R., Grant, C. S., Thompson, G. B., ... Van Heerden, J. A. (2001). Adrenocortical carcinoma: Surgical progress or status quo? Archives of Surgery, 136(5), 543-549.

Adrenocortical carcinoma : Surgical progress or status quo? / Kendrick, Michael L.; Lloyd, Ricardo; Erickson, Lori; Farley, David R.; Grant, Clive S.; Thompson, Geoffrey B.; Rowland, Charles; Young, William Francis; Van Heerden, Jon A.

In: Archives of Surgery, Vol. 136, No. 5, 2001, p. 543-549.

Research output: Contribution to journalArticle

Kendrick, ML, Lloyd, R, Erickson, L, Farley, DR, Grant, CS, Thompson, GB, Rowland, C, Young, WF & Van Heerden, JA 2001, 'Adrenocortical carcinoma: Surgical progress or status quo?', Archives of Surgery, vol. 136, no. 5, pp. 543-549.
Kendrick ML, Lloyd R, Erickson L, Farley DR, Grant CS, Thompson GB et al. Adrenocortical carcinoma: Surgical progress or status quo? Archives of Surgery. 2001;136(5):543-549.
Kendrick, Michael L. ; Lloyd, Ricardo ; Erickson, Lori ; Farley, David R. ; Grant, Clive S. ; Thompson, Geoffrey B. ; Rowland, Charles ; Young, William Francis ; Van Heerden, Jon A. / Adrenocortical carcinoma : Surgical progress or status quo?. In: Archives of Surgery. 2001 ; Vol. 136, No. 5. pp. 543-549.
@article{b659016858d24e33ba1f73383aa9c4bf,
title = "Adrenocortical carcinoma: Surgical progress or status quo?",
abstract = "Hypothesis: Outcome of patients with adrenocortical carcinoma (ACC) has improved with the advent of more widely available and higher quality imaging. Operative management strategies and use of adjuvant therapy have not changed. Design: Retrospective review of patient histories, imaging studies, operative data, adjuvant therapy, and outcomes at a single institution. Follow-up was complete for a mean of 53 months. Data was compared with prior institutional experience. Setting: Tertiary care referral center. Patients: All patients undergoing operative management for ACC during the period from 1980 to 1996. Main Outcome Measures: Determinants of recurrence, survival, and the effect of adjuvant therapy on overall outcome. Results: Fifty-eight patients (30 men, 28 women) with a mean age of 53 years underwent primary operative management for ACC. Functional tumors were identified in 27 patients (47{\%}). Mean tumor size was 12.5 cm. Stage according to the TNM staging system (AJCC Cancer Staging Manual) at presentation was I (n=0), II (n=30), III (n=7), and IV (n=21). Surgical management included curative resection in 41 (71{\%}), noncurative resection in 14 (24{\%}), and open biopsy in 3 (5{\%}). Perioperative mortality was 5{\%}. Recurrence occurred in 30 patients (73{\%}) with a median time to recurrence of 17 months. Five-year survival by the Kaplan-Meier method was 37{\%}. Prognostic factors (P<.05) included functional status, stage, and chemotherapy in stage III/IV patients. When compared with our prior institutional experience (1960-1980), current patients were more likely to present with stages I to II (52{\%} vs 34{\%}), have curative resections (71{\%} vs 50{\%}), and have improved 5-year survival (37{\%} vs 16{\%}). Conclusions: (1) Surgical resection remains the principal treatment for stage I to III disease. (2) Adjuvant therapy may improve survival in patients with stage III or IV disease. (3) Current patients were more likely to present at an earlier stage, undergo curative resections, and have improved 5-year survival than institutional historical comparisons.",
author = "Kendrick, {Michael L.} and Ricardo Lloyd and Lori Erickson and Farley, {David R.} and Grant, {Clive S.} and Thompson, {Geoffrey B.} and Charles Rowland and Young, {William Francis} and {Van Heerden}, {Jon A.}",
year = "2001",
language = "English (US)",
volume = "136",
pages = "543--549",
journal = "JAMA Surgery",
issn = "2168-6254",
publisher = "American Medical Association",
number = "5",

}

TY - JOUR

T1 - Adrenocortical carcinoma

T2 - Surgical progress or status quo?

AU - Kendrick, Michael L.

AU - Lloyd, Ricardo

AU - Erickson, Lori

AU - Farley, David R.

AU - Grant, Clive S.

AU - Thompson, Geoffrey B.

AU - Rowland, Charles

AU - Young, William Francis

AU - Van Heerden, Jon A.

PY - 2001

Y1 - 2001

N2 - Hypothesis: Outcome of patients with adrenocortical carcinoma (ACC) has improved with the advent of more widely available and higher quality imaging. Operative management strategies and use of adjuvant therapy have not changed. Design: Retrospective review of patient histories, imaging studies, operative data, adjuvant therapy, and outcomes at a single institution. Follow-up was complete for a mean of 53 months. Data was compared with prior institutional experience. Setting: Tertiary care referral center. Patients: All patients undergoing operative management for ACC during the period from 1980 to 1996. Main Outcome Measures: Determinants of recurrence, survival, and the effect of adjuvant therapy on overall outcome. Results: Fifty-eight patients (30 men, 28 women) with a mean age of 53 years underwent primary operative management for ACC. Functional tumors were identified in 27 patients (47%). Mean tumor size was 12.5 cm. Stage according to the TNM staging system (AJCC Cancer Staging Manual) at presentation was I (n=0), II (n=30), III (n=7), and IV (n=21). Surgical management included curative resection in 41 (71%), noncurative resection in 14 (24%), and open biopsy in 3 (5%). Perioperative mortality was 5%. Recurrence occurred in 30 patients (73%) with a median time to recurrence of 17 months. Five-year survival by the Kaplan-Meier method was 37%. Prognostic factors (P<.05) included functional status, stage, and chemotherapy in stage III/IV patients. When compared with our prior institutional experience (1960-1980), current patients were more likely to present with stages I to II (52% vs 34%), have curative resections (71% vs 50%), and have improved 5-year survival (37% vs 16%). Conclusions: (1) Surgical resection remains the principal treatment for stage I to III disease. (2) Adjuvant therapy may improve survival in patients with stage III or IV disease. (3) Current patients were more likely to present at an earlier stage, undergo curative resections, and have improved 5-year survival than institutional historical comparisons.

AB - Hypothesis: Outcome of patients with adrenocortical carcinoma (ACC) has improved with the advent of more widely available and higher quality imaging. Operative management strategies and use of adjuvant therapy have not changed. Design: Retrospective review of patient histories, imaging studies, operative data, adjuvant therapy, and outcomes at a single institution. Follow-up was complete for a mean of 53 months. Data was compared with prior institutional experience. Setting: Tertiary care referral center. Patients: All patients undergoing operative management for ACC during the period from 1980 to 1996. Main Outcome Measures: Determinants of recurrence, survival, and the effect of adjuvant therapy on overall outcome. Results: Fifty-eight patients (30 men, 28 women) with a mean age of 53 years underwent primary operative management for ACC. Functional tumors were identified in 27 patients (47%). Mean tumor size was 12.5 cm. Stage according to the TNM staging system (AJCC Cancer Staging Manual) at presentation was I (n=0), II (n=30), III (n=7), and IV (n=21). Surgical management included curative resection in 41 (71%), noncurative resection in 14 (24%), and open biopsy in 3 (5%). Perioperative mortality was 5%. Recurrence occurred in 30 patients (73%) with a median time to recurrence of 17 months. Five-year survival by the Kaplan-Meier method was 37%. Prognostic factors (P<.05) included functional status, stage, and chemotherapy in stage III/IV patients. When compared with our prior institutional experience (1960-1980), current patients were more likely to present with stages I to II (52% vs 34%), have curative resections (71% vs 50%), and have improved 5-year survival (37% vs 16%). Conclusions: (1) Surgical resection remains the principal treatment for stage I to III disease. (2) Adjuvant therapy may improve survival in patients with stage III or IV disease. (3) Current patients were more likely to present at an earlier stage, undergo curative resections, and have improved 5-year survival than institutional historical comparisons.

UR - http://www.scopus.com/inward/record.url?scp=0035022726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035022726&partnerID=8YFLogxK

M3 - Article

C2 - 11343545

AN - SCOPUS:0035022726

VL - 136

SP - 543

EP - 549

JO - JAMA Surgery

JF - JAMA Surgery

SN - 2168-6254

IS - 5

ER -